4.6 Review

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis

Journal

FRONTIERS IN MEDICINE
Volume 7, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2020.615599

Keywords

liver; fibrosis; macrophages; sCD163; mannose receptor; metabolic associated fatty liver disease; hepatitis B virus; hepatitis C virus

Funding

  1. Intercept
  2. Abbvie
  3. NOVO Nordisk Foundation
  4. Arla
  5. ADS AIPHIA Development Services AG

Ask authors/readers for more resources

Macrophages are crucial components of the human immune system, playing important roles in immune regulation and tissue repair. In liver diseases, they are involved in inflammation and fibrosis, with soluble CD163 and soluble mannose receptor potentially serving as promising biomarkers for assessing disease severity and predicting outcomes.
Macrophages are essential components of the human host immune system, which upon activation facilitates a broad pallet of immunomodulatory events including release of pro- or anti-inflammatory cytokines and chemokines, restoration of immune homeostasis and/or wound healing. Moreover, some macrophage phenotypes are crucially involved in fibrogenesis through stimulation of myofibroblasts, while others promote fibrolysis. During the last decades, the role of resident liver macrophages viz. Kupffer cells and recruited monocytes/macrophages in acute and chronic liver diseases has gained interest and been extensively investigated. Specifically, the scavenger receptors CD163 and mannose receptor (CD206), expressed by macrophages, are of utmost interest since activation by various stimuli induce their shedding to the circulation. Thus, quantifying concentrations of these soluble biomarkers may be of promising clinical relevance in estimating the severity of inflammation and fibrosis and to predict outcomes such as survival. Here, we review the existing literature on soluble CD163 and soluble mannose receptor in liver diseases with a particular focus on their relationship to hepatic fibrosis in metabolic associated fatty liver disease, as well as in chronic hepatitis B and C.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available